Day: June 24, 2022

The PGS ASA 2019 Long Term Incentive Plan (the “2019 LTI Plan”), under which Performance based Restricted Stock Units (“PRSUs”) were awarded to employees and primary insiders in PGS ASA and its subsidiaries (“PGS” or “the Company”), settled on June 23, 2022. PRSUs awarded to the below primary insiders under the 2019 LTI Plan have settled as follows: Rune Olav Pedersen, President & CEO, has received settlement of 40 748 PRSUs into an equal amount of shares in the Company. After completion of this transaction, he holds 1 057 000 PRSUs and 469 365 shares in the Company. Gottfred Langseth, EVP & CFO has received settlement of 18 191 PRSUs into an equal amount of shares in the Company. After completion of this transaction, he holds 446 000 PRSUs and 968 297 shares in the Company. Nathan Selvoy Oliver, EVP Sales...

24 June 2022 LEI: 2138003QW2ZAYZODBU23 WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE DAX® 30 3X DAILY LEVERAGED (ISIN: IE00B878KX55) WISDOMTREE DAX® 30 3X DAILY SHORT (ISIN: IE00B8GKPP93)together the “Affected Securities” NOTIFICATION OF CHANGE TO THE NAMES OF THE AFFECTED SECURITIES Terms not defined in this notice shall have the meaning ascribed to them in the Issuer’s Base Prospectus dated 1 November 2021. The Index in respect of the Affected Securities is LevDAX x3 TR Index (the “Underlying Index”). On 20 September 2022, the Underlying Index rebalanced and increased the constituents held by the Underlying Index from 30 constituents to 40 constituents (the “Rebalance”).  It is noted that the Affected Securities are impacted by the Rebalance as they...

At a recent ended employee election in Tryg, the Danish employees have elected Tina Snejbjerg and Charlotte Dietzer, the Norwegian employees Mette Osvold and the Swedish employees Elias Bakk and Lena Darin as employee representatives of Tryg’s Supervisory Board. As substitute members of Tryg’s Supervisory Board, the Danish employees have elected Jesper Henrik de Gusmão-Sørensen as personal substitute for Tina Snejbjerg, the Norwegian employees Bjørn Andreas Bøe Grønner as personal substitute for Mette Osvold and the Swedish employees have elected Simon Basdajian as personal substitute for Elias Bakk and Lars Eriksson as personal substitute for Lena Darin. The new board members enter the Supervisory Board on 1 July 2022. At the same time, the former employee representative Gert Ove Mikkelsen will withdraw. After 1 July 2022,...

Selskabsmeddelelse Nr. 12/2022 23. juni 2022 Indeholder intern videnEfter 6 måneders ejerskab af det vietnamesiske selskab Mermaid Maritime Vietnam Company Ltd. (“Mermaid”) har danske Erria optimeret driften og opjusterer nu EBITDA med DKK 3 mio. og hæver guidance for driftsresultatet fra 4-6 millioner kr. til 7-9 millioner kr. Driftsresultatet vil bidrage til positiv egenkapital fra tredje kvartal i 2022. Efter en overtagelsesproces på ca. 18 måneder købte børsnoterede Erria den 29. december 2021 selskabet Mermaid. Erria har siden sorteret ud i urentable kontrakter og driftsforhold (også kendt som Bad Will). Ledelsen i Erria kendte allerede til de fleste forpligtelser og utidssvarende driftskontrakter og -forhold allerede ved overtagelsen af Mermaid. På grund af den effektive driftsoptimering kan Erria nu meddele markedet en gevinst...

GUANGZHOU, China, June 24, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced the resignation of Mr. Jing Rong as a director from the Board, and the appointment of Dr. Licen Lisa Xu as an independent director to the Board. Dr. Xu has over 15 years of experience in driving the productization and lifecycle for life science and biomedical products, from conceptualization and research to development and commercialization. She is the chief commercial officer of FlashDx Inc., a molecular diagnostics point-of-care solution company, and an independent board member of Ribbon Biolab, a company specialized in the production of synthetic DNAs. Dr. Xu served...

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeM&C Saatchi Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Financial advisor and Broker to Advancedadvt Limited(d)        Date dealing undertaken:23rd June 2022(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash...

Please find below a press release from Aedifica (a public regulated real estate company under Belgian law, listed on Euronext Brussels and Euronext Amsterdam), regarding the successful private placement by way of an accelerated bookbuilding of 2,925,000 New Shares with international institutional investors. Please download the press release by clicking on the link below and by accepting the disclaimer. Press release ENCommuniqué de presse FRPersbericht NL

Availability of the Q2 2022 Memorandum for modelling purposes Paris, France – June 24, 2022 – Sanofi announced today that its Q2 2022 Memorandum for modelling purposes is available on the “Investors” page of the company’s website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q2-results-2022 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group’s quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi’s second-quarter 2022 results will be published on July 28, 2022. About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives....